Scott T. Tagawa, MD, Weill Cornell Medicine/New York-Presbyterian, discusses updated results from the IMMU-132 trial in metastatic urothelial cancer (mUC).
In the study, patients who were pretreated with platinum-containing chemotherapy received IMMU-132, an anti-Trop-2-SN-38 antibody-drug conjugate.
Of 44 patients, 36 are evaluable for response—which met the primary endpoint. At the time of these results, the response rate is above 30% and durable.
<<< View more from the 2017 Genitourinary Cancers Symposium